large study confirms that COVID-19 mRNA vaccines are safe in pregnancy
Written By : Isra Zaman
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2022-08-17 03:45 GMT | Update On 2024-02-15 13:22 GMT
This new study, from The Canadian National Vaccine Safety (CANVAS) Network, looked at data from participants across seven Canadian provinces and territories between December 2020 and November 2021. All vaccinated participants were asked to self-report any health events during the seven days following each dose of COVID-19 vaccine.The unvaccinated pregnant control group was asked to record...
Login or Register to read the full article
This new study, from The Canadian National Vaccine Safety (CANVAS) Network, looked at data from participants across seven Canadian provinces and territories between December 2020 and November 2021. All vaccinated participants were asked to self-report any health events during the seven days following each dose of COVID-19 vaccine.
The unvaccinated pregnant control group was asked to record any health problems over the seven days before they filled out the survey. In total, 191,360 women aged 15-49 years with known pregnancy status completed the first dose survey and 94,937 completed the second dose survey.
The researchers found that 4.0% (226/5,597) of mRNA-vaccinated pregnant females reported a significant health event within seven days after dose one of an mRNA vaccine, and 7.3% after dose two. The most common significant health events after dose two in pregnant females were a general feeling of being unwell, headache/migraine, and respiratory tract infection.
In comparison, 3.2% of pregnant unvaccinated participants reported similar events in the seven days prior to survey completion. In the vaccinated non-pregnant control group, 6.3% reported a significant health event in the week after dose one and 11.3% after dose two.
Ref:
Dr Julie Bettinger et. al, Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study, The Lancet Infectious Diseases, 11-Aug-2022
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd